#BEGIN_DRUGCARD DB01206

# AHFS_Codes:
10:00.00

# ATC_Codes:
L01AD02

# Absorption:
Well and rapidly absorbed from the gastrointestinal tract.

# Biotransformation:
Hepatic. Rapid and complete, with active metabolites.

# Brand_Mixtures:
Not Available

# Brand_Names:
Belustine
CINU
Cecenu
CeeNU

# CAS_Registry_Number:
13010-47-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C9H16ClN3O2

# Chemical_IUPAC_Name:
3-(2-chloroethyl)-1-cyclohexyl-3-nitrosourea

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
360414

# Description:
An alkylating agent of value against both hematologic malignancies and solid tumors. [PubChem]

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Antineoplastic Agents
Antineoplastic Agents, Alkylating

# Drug_Interactions:
Atomoxetine	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
Bendamustine	Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.
Terbinafine	Terbinafine may reduce the metabolism and clearance of Lomustine. Consider alternate therapy or monitor for therapeutic/adverse effects of Lomustine if Terbinafine is initiated, discontinued or dose changed.
Trastuzumab	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.83

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
111 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Lomustine

# HET_ID:
Not Available

# Half_Life:
Approximately 94 minutes, however the metabolites have a serum half-life of 16 to 48 hours.

# InChI_Identifier:
InChI=1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)

# InChI_Key:
InChIKey=GQYIWUVLTXOXAJ-UHFFFAOYSA-N

# Indication:
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00363

# LIMS_Drug_ID:
1206

# Mechanism_Of_Action:
Lomustine is a highly lipophilic nitrosourea compound which undergoes hydrolysis in vivo to form reactive metabolites. These metabolites cause alkylation and cross-linking of DNA (at the O6 position of guanine-containing bases) and RNA, thus inducing cytotoxicity. Other biologic effects include inhibition of DNA synthesis and some cell cycle phase specificity. Nitrosureas generally lack cross-resistance with other alkylating agents. As lomustine is a nitrosurea, it may also inhibit several key processes such as carbamoylation and modification of cellular proteins.

# Melting_Point:
88-90 Â°C

# Molecular_Weight_Avg:
233.695

# Molecular_Weight_Mono:
233.093104478

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164749407

# Pharmacology:
Lomustine is an alkylating agent of the nitrosourea type. Lomustine and its metabolites interferes with the function of DNA and RNA. It is cell cycle&ndash;phase nonspecific. Cancers form when some cells within the body multiply uncontrollably and abnormally. These cells then spread and destroy nearby tissues. Lomustine acts by slowing this process down. It kills cancer cells by damaging the DNA (the genetic material inside the cells) and stops them from dividing.

# Predicted_LogP_Hydrophobicity:
2.62

# Predicted_LogS:
-2.5

# Predicted_Water_Solubility:
7.55e-01 g/l

# Primary_Accession_No:
DB01206

# Protein_Binding:
50%

# PubChem_Compound_ID:
3950

# PubChem_Substance_ID:
46506562

# RxList_Link:
http://www.rxlist.com/cgi/generic2/lomustine.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00292

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
ClCCN(N=O)C(=O)NC1CCCCC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
CCNU
Chloroethylcyclohexylnitrosourea
Lomustina [INN-Spanish]
Lomustinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Oral, rat: LD<sub>50</sub> = 70 mg/kg. Pulmonary toxicity has been reported at cumulative doses usually greater than 1,100 mg/m2. There is one report of pulmonary toxicity at a cumulative dose of only 600 mg. The onset of toxicity has varied from 6 months after initiation of therapy, to as late as 15 years after.

# Update_Date:
2013-02-08 16:20:00 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Lomustine

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_1_ID:
4119

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P10635

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_2_ID:
4512

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P08684

# Drug_Target_1_Cellular_Location:
Nucleus and mitochondria

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11007934	Spiro T, Liu L, Gerson S: New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance. Forum (Genova). 2000 Jul-Sep;10(3):274-85.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17146474	Larkin JM, Hughes SA, Beirne DA, Patel PM, Gibbens IM, Bate SC, Thomas K, Eisen TG, Gore ME: A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer. 2007 Jan 15;96(1):44-8. Epub 2006 Dec 5.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>Example: Dickerson dodecamer
CGCGAATTCGCG

# Drug_Target_1_General_Function:
Biological information storage and information transfer

# Drug_Target_1_General_References:
1234	Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
874

# Drug_Target_1_Locus:
All loci

# Drug_Target_1_Molecular_Weight:
7656 (double strand)

# Drug_Target_1_Name:
DNA

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
1BNA

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Deoxyribonucleic acid

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
8

# Drug_Target_2_Drug_References:
18162179	Wu WW, Wang G, Liang XJ, Park JK, Shen RF: Covalent modification of stathmin by CCNU determined by FTMS analysis of modified proteins and tryptic peptides. Biochem Biophys Res Commun. 2008 Feb 29;367(1):7-13. Epub 2007 Dec 26.
18593927	Liang XJ, Choi Y, Sackett DL, Park JK: Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells. Cancer Res. 2008 Jul 1;68(13):5267-72.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AJ303455

# Drug_Target_2_GenBank_ID_Protein:
12274941

# Drug_Target_2_GeneCard_ID:
STMN4

# Drug_Target_2_Gene_Name:
STMN4

# Drug_Target_2_Gene_Sequence:
>570 bp
ATGACCCTTGCTGCCTACAAAGAGAAGATGAAGGAGCTCCCGCTGGTGTCCTTGTTCTGC
TCCTGCTTCCTGGCCGATCCCCTGAATAAGTCGTCCTACAAATATGAAGCAGACACGGTG
GACCTGAATTGGTGCGTCATTTCCGACATGGAAGTCATCGAGCTGAACAAATGCACCTCG
GGCCAATCCTTTGAAGTCATCCTGAAGCCACCCTCCTTTGATGGGGTTCCCGAGTTCAAC
GCCTCCCTGCCAAGGCGGCGAGACCCATCCCTGGAAGAGATCCAGAAGAAACTAGAAGCG
GCTGAGGAGCGAAGGAAGTACCAGGAAGCGGAGCTCCTGAAACACCTAGCAGAGAAACGG
GAACATGAGAGAGAGGTGATCCAAAAGGCCATTGAGGAAAACAACAACTTCATCAAGATG
GCTAAGGAAAAACTGGCCCAGAAGATGGAATCCAACAAGGAGAACAGGGAGGCCCACCTC
GCCGCCATGTTGGAACGGCTGCAAGAGAAGGACAAGCACGCCGAGGAGGTGCGGAAAAAC
AAGGAGCTGAAGGAAGAGGCCTCCAGGTAA

# Drug_Target_2_General_Function:
Involved in intracellular signaling cascade

# Drug_Target_2_General_References:
11230166	Wiemann S, Weil B, Wellenreuther R, Gassenhuber J, Glassl S, Ansorge W, Bocher M, Blocker H, Bauersachs S, Blum H, Lauber J, Dusterhoft A, Beyer A, Kohrer K, Strack N, Mewes HW, Ottenwalder B, Obermaier B, Tampe J, Heubner D, Wambutt R, Korn B, Klein M, Poustka A: Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs. Genome Res. 2001 Mar;11(3):422-35.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.

# Drug_Target_2_HGNC_ID:
GNC:16078

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6506

# Drug_Target_2_Locus:
8p21.2

# Drug_Target_2_Molecular_Weight:
22071.0

# Drug_Target_2_Name:
Stathmin-4

# Drug_Target_2_Number_of_Residues:
189

# Drug_Target_2_PDB_ID:
1SA1

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00836	Stathmin

# Drug_Target_2_Protein_Sequence:
>Stathmin-4
MTLAAYKEKMKELPLVSLFCSCFLADPLNKSSYKYEADTVDLNWCVISDMEVIELNKCTS
GQSFEVILKPPSFDGVPEFNASLPRRRDPSLEEIQKKLEAAEERRKYQEAELLKHLAEKR
EHEREVIQKAIEENNNFIKMAKEKLAQKMESNKENREAHLAAMLERLQEKDKHAEEVRKN
KELKEEASR

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Q9H169

# Drug_Target_2_SwissProt_Name:
STMN4_HUMAN

# Drug_Target_2_Synonyms:
RB3
Stathmin-like protein B3

# Drug_Target_2_Theoretical_pI:
5.81

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01206
